In addition to direct therapy against AML, our results also demonstrate expression of FRβ on TAMs from 15 individual ovarian ascites samples as well as the ability for m909 to cause ADCC of TAMs in a dose-dependent manner. The gene discussed is FOLR2; the disease is acute myeloid leukemia.